Finance

Lists
AMG:ETR
Amgen Inc
၃၆၁.၈၀ €
+၁.၄၇%
(+၅.၂၅) 1D
အောက် ၆, GMT+၂ ၁၀:၅၈:၄၁  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG...
Open
၃၅၉.၆၀ €
High
၃၆၄.၅၀ €
Low
၃၅၉.၆၀ €
Mkt. cap
ဋေ ၂.၁၈ သ
Avg. vol.
၄၇၃.၀၀
Volume
၁.၀၆ ထောင်
52-wk high
၃၈၃.၀၅ €
52-wk low
၂၄၇.၆၅ €
No. of employees
၃ သောင်း
Open
၃၅၉.၆၀ €
High
၃၆၄.၅၀ €
Low
၃၅၉.၆၀ €
Mkt. cap
ဋေ ၂.၁၈ သ
Avg. vol.
၄၇၃.၀၀
Volume
၁.၀၆ ထောင်
52-wk high
၃၈၃.၀၅ €
52-wk low
၂၄၇.၆၅ €
No. of employees
၃ သောင်း
News stories
From web sources and news partners
MarketBeat
MarketBeat
·
ပြီးခဲ့သည့် ၂ နာရီ
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB
AD HOC NEWS
AD HOC NEWS
·
ပြီးခဲ့သည့် ၂ နာရီ
Amgen stock pre-market at EUR 360.03: plus 0.28 percent
Kalkine Media
Kalkine Media
·
ပြီးခဲ့သည့် ၁၅ နာရီ
Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances?
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees၃.၁၅ သောင်း
Founded၁၉၈၀
Headquartersသောင်စင်အုက်စ်, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteamgen.com
Last report
၂၀၂၆ ဩ ၄
Fiscal period
Q2 2026
EPS / Est. (USD)
၆.၂၉ US$ / ၅.၆၂ US$
+၁၁.၉၇%beat
Revenue / Est. (USD)
ဋေ ၁.၀၁ ထ / ၉၄၂.၀၂ ဋေ
+၆.၇၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၉၅၅.၇၀ ဋေ
၉၈၆.၆၀ ဋေ
၈၆၁.၈၀ ဋေ
ဋေ ၁.၀၁ ထ
Cost of goods sold
၂၇၄.၄၀ ဋေ
၂၆၇.၆၀ ဋေ
၂၄၉.၇၀ ဋေ
၂၇၅.၁၀ ဋေ
Cost of revenue
၂၇၄.၄၀ ဋေ
၂၆၇.၆၀ ဋေ
၂၄၉.၇၀ ဋေ
၂၇၅.၁၀ ဋေ
Research and development expenses
၁၉၀.၀၀ ဋေ
၂၁၄.၂၀ ဋေ
၁၇၁.၉၀ ဋေ
၁၈၆.၈၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၇၂.၀၀ ဋေ
၁၉၅.၂၀ ဋေ
၁၆၀.၂၀ ဋေ
၁၇၄.၅၀ ဋေ
Operating expense
၃၅၄.၉၀ ဋေ
၄၁၇.၆၀ ဋေ
၃၂၀.၈၀ ဋေ
၃၇၂.၉၀ ဋေ
Total operating expenses
၆၂၉.၃၀ ဋေ
၆၈၅.၂၀ ဋေ
၅၇၀.၅၀ ဋေ
၆၄၈.၀၀ ဋေ
Operating income
၃၂၆.၄၀ ဋေ
၃၀၁.၄၀ ဋေ
၂၉၁.၃၀ ဋေ
၃၅၇.၄၀ ဋေ
Other non operating income
၁၈.၁၀ ကုဋေ
၁၄.၃၀ ကုဋေ
၁၉.၂၀ ကုဋေ
၁၄.၅၀ ကုဋေ
EBT including unusual items
၃၉၂.၁၀ ဋေ
၁၅၁.၄၀ ဋေ
၂၀၈.၄၀ ဋေ
၂၇၆.၈၀ ဋေ
EBT excluding unusual items
၂၇၂.၁၀ ဋေ
၂၅၀.၉၀ ဋေ
၂၃၇.၁၀ ဋေ
၃၀၅.၅၀ ဋေ
Income tax expense
၇၀.၅၀ ကုဋေ
၁၈.၁၀ ကုဋေ
၂၆.၅၀ ကုဋေ
၃၉.၃၀ ကုဋေ
Effective tax rate
၁၇.၉၈%
၁၁.၉၆%
၁၂.၇၂%
၁၄.၂၀%
Other operating expenses
-၇.၁၀ ကုဋေ
၈.၂၀ ကုဋေ
-၁၁.၃၀ ကုဋေ
၁၁.၆၀ ကုဋေ
Net income
၃၂၁.၆၀ ဋေ
၁၃၃.၃၀ ဋေ
၁၈၁.၉၀ ဋေ
၂၃၇.၅၀ ဋေ
Net profit margin
၃၃.၆၅%
၁၃.၅၁%
၂၁.၁၁%
၂၃.၆၂%
Earnings per share
၅.၆၄
၅.၂၉
၅.၁၅
၆.၂၉
Interest and investment income
-
၄၀.၈၀ ကုဋေ
-
-
Interest expense
-၆၈.၅၀ ကုဋေ
-၁၀၆.၁၀ ဋေ
-၆၅.၇၀ ကုဋေ
-၆၇.၃၀ ကုဋေ
Net interest expenses
-၆၈.၅၀ ကုဋေ
-၆၅.၃၀ ကုဋေ
-၆၅.၇၀ ကုဋေ
-၆၇.၃၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၅၇.၁၀ ဋေ
၄၀၂.၂၀ ဋေ
၄၀၂.၉၀ ဋေ
၄၆၈.၆၀ ဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ